CXCR3 and neoplasm: We also note with interest that recent publications highlight the importance of tumoral chemotaxis of CXCR3 bearing T-cells for preclinical and clinical responsiveness to T-cell checkpoint inhibitors.26–28 Elevated expression of PDCD1 (PD-1) infer tumoral T-cells in those CT26 tumor bearing mice are likely activated and/or exhausted and strongly support the inclusion of aPD-L1 to counteract adaptive immune-resistance to anti-tumor effects.